Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART22-65s and huCART19 in Relapsed or Refractory B-ALL
NCT05674175Phase 2Recruiting
- Start
- Jan 2023
- Primary completion
- Jul 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD22-CAR-T, huCART-19 in B cell acute lymphoblastic leukemia (B-ALL), B-cell lymphoblastic lymphoma (B-LBL). Started Jan 2023; status: recruiting.
02
Drugs
CD22-CAR-ThuCART-19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT05674175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674175.